Influenza

There are 300 papers on influenza in aging research: 22 trials and 110 observational studies in people, 91 in animals, 5 in cells, 61 reviews. The newest story, Oct 30, 2026: “Blood aging clock maps aging-like changes in COVID-19”.

Disease

300 papers study it431 more mention it46 findings

26 new papers in 30 daysSee all 731 papers on influenza

At a glance

Severe influenza requiring hospitalization is associated with worsening frailty at discharge and reduced functional independence after rehabilitation. Human studies link influenza with mortality; frailty is linked with greater influenza risk, but a study finds no clear frailty link. A human trial reports protection with high-dose vaccine; transferring lung ILC2 from young mice protects old mice.

46 findings in 40 papers from 2016 to 2026, 6 of them since June 2026

“incidence of early acute ischemic stroke following coronavirus disease 2019 (PCORnet: 962 per 100,000; HealthVerity: 447 per 100,000) and influenza (PCORnet: 589 per 100,000; HealthVerity: 387 per 100,000) was significantly higher”
Acute ischemic stroke incidence after influenza or coronavirus disease 2019 among older US adults: A cross-sectional study using electronic health recordsThe Journal of international medical research2026doi:10.1177/03000605261416675
  • Human trial22
  • Humans110
  • Animals91
  • Cells5
  • In silico10

Interventions

14

High-dose inactivated influenza vaccine

downin humans1HR 0.55

1 study
  1. High-dose inactivated influenza vaccine protects against influenza in patients with hypertension (HR 0.55 [0.24–1.25]).

    “In patients with HTN, HD‐IIV was associated with a 45% lower risk of hospitalization for pneumonia or influenza”

    Human trialin patients with hypertensionmedian follow‐up of 223 daysn = 6,469

    High-Dose vs. Standard-Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU-1

    Journal of clinical hypertension (Greenwich, Conn.)

  2. High-dose inactivated influenza vaccine protects against influenza in humans.

    “HD-IIV was associated with lower hazards for hospitalizations for pneumonia or influenza, respiratory disease, and all-cause mortality compared with SD-IIV”

    Human trial

    High-Dose vs. Standard-Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU-1

    Journal of clinical hypertension (Greenwich, Conn.)

More on High-dose inactivated influenza vaccine

Amnesti

downin mice1

1 study
  1. Amnesti protects against influenza in mice (adjuvant for inactivated influenza vaccine, single intranasal dose) (complete protection).

    “A single intranasal dose of AMnESTI-adjuvanted influenza vaccine conferred complete heterosubtypic protection in aged mice against representative influenza strains.”

    Animalsadjuvant for inactivated influenza vaccine, single intranasal dosesingle intranasal dose

    AMnESTI reverses age-associated lung immune decline to drive heterosubtypic protection by inactivated influenza vaccines

    Science immunology

More on Amnesti

Bone marrow-derived macrophage transfer

no changein mice1

1 study
  1. Bone marrow-derived macrophage transfer showed no clear effect on influenza in mice (against mismatched viral challenge).

    “However, this restoration does not improve protection against mismatched viral challenge, suggesting additional age-related immune impairments.”

    Animalsagainst mismatched viral challenge

    Muscle macrophage regenerative response after squalene-adjuvanted influenza vaccination drives Th2-skewed response and is reduced with age

    Research SquarePreprint

More on Bone marrow-derived macrophage transfer

Cgamp

downin mice1

1 study
  1. Cgamp protects against influenza in mice (mouse challenge models of influenza A (H1N1 or highly pathogenic H5N1) and influenza B).

    “NanoSTING provided therapeutic protection at least as effective as ten doses of oseltamivir.”

    Animalsmouse challenge models of influenza A (H1N1 or highly pathogenic H5N1) and influenza Bliposomally encapsulated cGAMP

    Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains

    Antiviral research

More on Cgamp

Mesenchymal stromal cells

downin mice1

1 study
  1. Mesenchymal stromal cells protect against influenza in mice.

    “This significantly protected aging mice from influenza infection.”

    Animals

    Mesenchymal stromal cells counteract with age-related immune decline and enhance vaccine efficacy by modulating endogenous splenic marginal reticular cells in elderly models

    Cellular & molecular immunology

More on Mesenchymal stromal cells

Cobra H1/H3 ha + TRAC478 or sas

downin M. putorius1

1 study
  1. Cobra H1/H3 ha + TRAC478 or sas protect against influenza in M. putorius following influenza virus challenge.

    “These elderly ferrets were protected following challenge with influenza virus with little to no detectable signs of disease or weight loss.”

    Animalsfollowing influenza virus challenge

    Elicitation of protective immune responses against influenza a viruses in elderly ferrets by adjuvanted recombinant universal influenza hemagglutinin vaccines

    Immunity & ageing : I & A

More on Cobra H1/H3 ha + TRAC478 or sas

Trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix

downin mice1

1 study
  1. Trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix protects against influenza in mice (H1N1pdm09-like virus challenge).

    “Overall, TIV-IMXQB improved the immunogenicity compared to TIV by enhancing systemic and mucosal immunity in old mice conferring a faster recovery after the H1N1pdm09-like virus challenge.”

    AnimalsH1N1pdm09-like virus challenge

    Intranasal Delivery of Quillaja brasiliensis Saponin-Based Nanoadjuvants Improve Humoral Immune Response of Influenza Vaccine in Aged Mice

    Vaccines

More on Trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix

High-dose influenza vaccine

downin humans1

1 study
  1. High-dose influenza vaccine prevents influenza in the context of immunosenescence.

    “high-dose (HD) influenza vaccines have demonstrated their safety and are more effective in preventing influenza and its associated complications compared to standard-dose (SD) vaccines in the elderly”

    Reviewin the context of immunosenescence

    Protecting the elderly from influenza in the context of immune system senescence. Elderly aged 65 and over are vulnerable to influenza and its associated complications.: Position paper by the Romanian Society of Gerontology and Geriatrics

    Journal of medicine and life

More on High-dose influenza vaccine

Cpg + monophosphoryl lipid A

downin mice1

1 study
  1. Cpg + monophosphoryl lipid A protects against influenza in mice (influenza vaccination).

    “enhanced homologous and cross-protection by influenza vaccination in adult and aged mouse models.”

    Animalsinfluenza vaccination

    Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice

    Antiviral research

More on Cpg + monophosphoryl lipid A

QS-21 + monophosphoryl lipid A

downin mice1

1 study
  1. QS-21 + monophosphoryl lipid A protects against influenza in mice (influenza vaccination).

    “enhanced homologous and cross-protection by influenza vaccination in adult and aged mouse models.”

    Animalsinfluenza vaccination

    Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice

    Antiviral research

More on QS-21 + monophosphoryl lipid A

All 14

Effects

6

Mortality

upin humans2

2 studies
  1. Influenza is linked with higher mortality in humans (postpandemic period (2023-2025)).

    “influenza-associated deaths increased and RSV mortality rose modestly”

    Humanspostpandemic period (2023-2025)

    Shifting patterns of acute respiratory infection mortality in Australia: Changing contributions of COVID-19, influenza, and respiratory syncytial virus, and persistent Indigenous inequalities

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

  2. Influenza is linked with higher mortality in humans (US residents, 2018-2020) (average of 7,670 deaths per year, mean death rate of 2.3 × 100,000).

    “Influenza caused an average of 7,670 deaths per year from 2018 to 2020 based on Influenza-specific ICD-10 codes, with a corresponding mean death rate of 2.3 × 100,000.”

    HumansUS residents, 2018-2020

    Updated statistics on Influenza mortality

    Diagnosis (Berlin, Germany)

30-day all-cause mortality

no changein humans1

1 study
  1. Influenza was not clearly linked with 30-day all-cause mortality in humans (aOR 0.82; p=0.86).

    “COVID-19 (aOR 1.59; p=0.21) and influenza (aOR 0.82; p=0.86) were not significantly associated with 30-day all-cause mortality”

    HumansPatients with heart failure hospitalized for acute respiratory symptoms; compared with non-infectious diseases30 days55.7% malesn = 977

    Prognostic impact of respiratory infection status on 30-day mortality in older heart failure patients hospitalised for acute respiratory symptoms: a sub-analysis of the EVERY prospective cohort study

    ESC Congress 2026 abstract

Pro-inflammatory cytokines

upin humans1

1 study
  1. Influenza is linked with higher pro-inflammatory cytokines in humans (acute respiratory infection (mostly confirmed influenza)).

    “The results illustrated that pro-inflammatory cytokines were found to be significantly elevated in infected individuals”

    Humansacute respiratory infection (mostly confirmed influenza)

    Serum Cytokines During Acute Respiratory Infection and Relationship to Age

    Journal of cellular immunology

More on Pro-inflammatory cytokines

Physical function

downin humans1−10%

1 study
  1. Influenza impairs physical function in humans (frail) (up to 10%).

    “Influenza might drive significant functional loss in frail older adults, which can lead to "catastrophic" or severe disability in up to 10% of patients.”

    Reviewfrail

    Burden of influenza in the elderly: a narrative review

    Current opinion in infectious diseases

Myocardial infarction

upin humans1

1 study
  1. Influenza induces myocardial infarction in humans.

    “Beyond respiratory complications, influenza triggers acute myocardial infarction and ischemic stroke.”

    Review

    Burden of influenza in the elderly: a narrative review

    Current opinion in infectious diseases

More on Myocardial infarction

Frailty

no changein humans1OR 0.5

1 study
  1. Influenza was not clearly linked with frailty in humans (frail vs nonfrail participants) (OR 0.50, 95% CI 0.17-1.43).

    “Frailty was not associated with influenza, with an OR of 0.50 (95% CI 0.17-1.43) for frail participants compared to nonfrail participants.”

    Humansfrail vs nonfrail participants

    Influenza infection is not associated with phenotypical frailty in older patients, a prospective cohort study

    Health science reports

Upstream

1

Hemagglutinin stalk-reactive antibodies

downin mice1

1 study
  1. Hemagglutinin stalk-reactive antibodies protect against influenza in mice (passive-transfer model, titer-dependent).

    “the stalk antibodies measured by enzyme-linked immunosorbent assay (ELISA) showed neutralizing activity in neutralization assays and protected mice in a passive-transfer model in a stalk titer-dependent manner”

    Animalspassive-transfer model, titer-dependent

    Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans

    mBio

More on Hemagglutinin stalk-reactive antibodies

Associations

13

Influenza vaccine

downin humans5−25%HR 0.7–0.99

5 studies
  1. Influenza vaccine is linked with a lower risk of influenza in the 2017/2018 and 2018/2019 seasons.

    “Delayed vaccination was associated with the lowest influenza incidence in the 2017/2018 and 2018/2019, but not in the other seasons.”

    Humansin the 2017/2018 and 2018/2019 seasons

    Assessment of timing for influenza vaccination among older adults in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

  2. Influenza vaccine is linked with a lower risk of influenza in humans (VE 56%).

    “Adjusted analyses showed significant protection in children ≤ 15 years and adults < 65 years, with VE of 56 % and 51 %, respectively.”

    Humans

    Influenza vaccine effectiveness over 17 seasons in a large Japanese cohort: Analyses by age, virus type, underlying diseases and seasons before the COVID-19 pandemic

    Journal of infection and public health

  3. Influenza vaccine is linked with a lower risk of influenza in humans (HR 0.70 to 0.99).

    “Vaccination was moderately effective against influenza, the prior event rate ratio-adjusted hazard ratios ranging from 0.70 in 1999 to 0.99 in 2001.”

    Humans

    Influenza vaccination reduced myocardial infarctions in United Kingdom older adults: a prior event rate ratio study

    Journal of clinical epidemiology

  4. Influenza vaccine lowers the risk of influenza in humans (25%).

    “The unadjuvanted, standard-dose influenza vaccine had an estimated effectiveness of just 25% against laboratory-confirmed influenza”

    Reviewunadjuvanted, standard-dose

    Influenza disease burden and the need for highly immunogenic vaccines in older adults: a narrative review

    Ewha medical journal

  5. Influenza vaccine lowers the risk of influenza in humans among the elderly.

    “primary prevention via immunization is effective in reducing the burden of influenza illness among the elderly”

    Reviewamong the elderly

    Influenza vaccination in the elderly

    Human vaccines & immunotherapeutics

More on Influenza vaccine

Mortality

upin humans5+48% deaths occurred after hospital discharge

5 studies
  1. Influenza is associated with mortality in humans (48% of deaths occurred after hospital discharge).

    “Among all patients with an influenza-associated hospitalization who died, 48% of deaths occurred after hospital discharge”

    Humanswithin 30 days post discharge

    The Burden of All-Cause Mortality Following Influenza-Associated Hospitalizations: Influenza Hospitalization Surveillance Network, 2010-2019

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

  2. Influenza is associated with mortality in humans (between week 33, 2022 through week 12, 2023).

    “we estimated 7851 (5213,10463) influenza-associated deaths”

    Humansbetween week 33, 2022 through week 12, 2023

    Mortality associated with influenza and Omicron infections in France and vaccination of healthcare workers in nursing homes

    medRxivPreprint

  3. Influenza is associated with mortality in humans (mainland China, 2011 to 2016) (151.6 (95% CI: 127.6-179.3) per 100,000 persons).

    “estimates of annual national average influenza-associated excess R&C and AC mortality among older adults aged 65 years and above were 111.8 (95% CI: 92.8-141.1) and 151.6 (95% CI: 127.6-179.3) per 100,000 persons”

    Humansmainland China, 2011 to 2016

    Estimating mortality associated with seasonal influenza among adults aged 65 years and above in China from 2011 to 2016: A systematic review and model analysis

    Influenza and other respiratory viruses

  4. Influenza is linked with a higher risk of mortality in humans (seasonal influenza) (113.6 [CI 49.5-397.4] versus 4.4 [CI 1.7-18.6] per 100 000, P < .05).

    “the influenza-associated mortality rate in this age group was higher than the rate among those aged <65 years (113.6 [CI 49.5-397.4] versus 4.4 [CI 1.7-18.6] per 100 000, P < .05)”

    Humansseasonal influenza

    Mortality burden from seasonal influenza and 2009 H1N1 pandemic influenza in Beijing, China, 2007-2013

    Influenza and other respiratory viruses

  5. Influenza raises the risk of mortality in humans.

    “In older adults, influenza frequently results in hospitalization and death, which is exacerbated by immunosenescence and biological organ changes associated with aging.”

    Review

    Influenza and Aging: Clinical Manifestations, Complications, and Treatment Approaches in Older Adults

    Drugs & aging

Frailty

upin humans2RR 1.36

2 studies
  1. Influenza is associated with frailty in humans (severe influenza requiring hospitalization) (CFS worsened in 19 cases (9.0%)).

    “The CFSs worsened in 19 cases (9.0%) at the time of discharge.”

    Humanssevere influenza requiring hospitalizationat dischargen = 210

    Outcomes of elderly hospitalized patients with influenza after the COVID-19 pandemic: decline of functional independence and frailty

    Respiratory investigation

  2. Frailty is linked with a higher risk of influenza in humans (RR 1.36, 95% CI 1.20-1.53).

    “Frailty was associated with both influenza and the hospitalization among the older adults compared with nonfrail individuals after adjusting for covariates (influenza, frail: risk ratio {RR}: 1.36”

    Humans

    Association of frailty with influenza and hospitalization due to influenza among independent older adults: a longitudinal study of Japan Gerontological Evaluation Study (JAGES)

    BMC geriatrics

Functional independence

downin humans1

1 study
  1. Influenza is associated with functional independence in humans (severe influenza requiring hospitalization) (37 cases (17.6%) had FIM scores below 70 after rehabilitation).

    “the functional independence measure (FIM) of 37 cases (17.6%) remained under a score of 70 even after rehabilitation.”

    Humanssevere influenza requiring hospitalizationafter rehabilitationn = 210

    Outcomes of elderly hospitalized patients with influenza after the COVID-19 pandemic: decline of functional independence and frailty

    Respiratory investigation

In-hospital mortality

upin humans1

1 study
  1. Influenza is associated with in-hospital mortality in humans (severe influenza requiring hospitalization) (17 patients (8.1%) died in hospital).

    “in-hospital deaths were recorded for 17 patients (8.1%).”

    Humanssevere influenza requiring hospitalizationn = 210

    Outcomes of elderly hospitalized patients with influenza after the COVID-19 pandemic: decline of functional independence and frailty

    Respiratory investigation

Cardiovascular mortality

upin humans1

1 study
  1. Influenza is associated with cardiovascular mortality in humans (influenza-associated burden) (more than 50 deaths per 100 000 older adults).

    “Cardiovascular events were particularly notable, contributing to more than 50 deaths and 60 hospitalisations per 100 000 older adults.”

    Reviewinfluenza-associated burden

    Estimating the population-level non-respiratory burden of severe influenza: a systematic review of methods and estimates

    The lancet. Healthy longevity

Acute ischemic stroke

upin humans1

1 study
  1. Influenza is linked with a higher risk of acute ischemic stroke in humans (early (-3 to 7 days) vs late (8 to 28 days) post-diagnosis) (PCORnet: 589 vs 75 per 100,000; HealthVerity: 387 vs 15 per 100,000).

    “incidence of early acute ischemic stroke following coronavirus disease 2019 (PCORnet: 962 per 100,000; HealthVerity: 447 per 100,000) and influenza (PCORnet: 589 per 100,000; HealthVerity: 387 per 100,000) was significantly higher”

    Humansearly (-3 to 7 days) vs late (8 to 28 days) post-diagnosis

    Acute ischemic stroke incidence after influenza or coronavirus disease 2019 among older US adults: A cross-sectional study using electronic health records

    The Journal of international medical research

More on Acute ischemic stroke

Statins

upin humans1OR 1.15

1 study
  1. Statins are linked with a higher risk of influenza in vaccinated older adults (OR 1.15, 95% CI 1.10-1.21).

    “In both vaccinated and unvaccinated persons, statin users had higher odds of laboratory-confirmed influenza than nonusers (odds ratios for vaccinated and unvaccinated persons 1.15 [95% confidence interval, 1.10-1.21] and 1.15 [1.10-1.20], respectively).”

    Humansin vaccinated older adults

    Evaluating the Impact of Statin Use on Influenza Vaccine Effectiveness and Influenza Infection in Older Adults

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

More on Statins

Cellular senescence

upin humans1

1 study
  1. Influenza is associated with cellular senescence in humans (severe viral pulmonary infections).

    “Influenza virus infection, which strikes more severely at the extreme ages of life, is also associated with severe pulmonary senescence.”

    Reviewsevere viral pulmonary infectionslung

    Cell senescence, a new target for respiratory viral infections: From influenza virus to SARS-CoV-2

    Bulletin de l'Academie nationale de medecine

More on Cellular senescence

Respiratory and circulatory mortality

upin humans1

1 study
  1. Influenza is associated with respiratory and circulatory mortality in humans (mainland China, 2011 to 2016) (111.8 (95% CI: 92.8-141.1) per 100,000 persons).

    “estimates of annual national average influenza-associated excess R&C and AC mortality among older adults aged 65 years and above were 111.8 (95% CI: 92.8-141.1) and 151.6 (95% CI: 127.6-179.3) per 100,000 persons”

    Humansmainland China, 2011 to 2016

    Estimating mortality associated with seasonal influenza among adults aged 65 years and above in China from 2011 to 2016: A systematic review and model analysis

    Influenza and other respiratory viruses

All 13

Trial sponsors

Funding

48 grants since 2016

National Institute of Allergy and Infectious Diseases$46.2MNational Institute on Aging$18.5MNational Heart, Lung, and Blood Institute$301K

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 13Jan 2026: 11Feb 2026: 16Mar 2026: 19Apr 2026: 10May 2026: 9Jun 2026: 13Jul 2026: 13Aug 2026: 14Sep 2026: 9Oct 2026: 19Nov 2026: 11157 papers in 12 months
Briefings in Bioinformatics

Blood aging clock maps aging-like changes in COVID-19

People with COVID-19 had blood gene-activity age estimates averaging 9.34 years above a healthy-aging reference after correction for each cohort’s baseline.People with COVID-19 had blood gene-activity age estimates averaging 9.34 years above a healthy-aging reference after correction for each cohort’s baseline.

Cross-sectional · 469 peopleCOVID-19

See all 731 papers on influenza